Safety of Intravenous Thrombolytics in Stroke on Awakening

Status: Completed
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The primary objective of this study is to evaluate the safety of intravenous tissue plasminogen activator (IV tPA) in patients waking up with symptoms of acute stroke and presenting to the Emergency Department (ED) within 4.5 hours from awakening, and meeting standard criteria for treatment with IV tPA for acute stroke. The hypothesis is that patients that wake up with stroke symptoms may have developed the stroke at the time of awakening, and may be within the 4.5 hour window if they arrive to the ED within that time, therefore IV tPA should be safe and effective in this population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age greater or equal to 18 years, and lower or equal to 80 years.

• Signs and symptoms of acute ischemic stroke.

• Symptoms present upon awakening.

• Arriving to the Emergency Department within 4.5 hours of awakening. Treatment with IV tPA must be initiated prior to 4.5hours from waking up.

• NIHSS \>3

• A non-contrast head CT without hemorrhage and without hypodensity more than 1/3 of the middle cerebral artery (MCA) territory; or MRI demonstrating no hemorrhage, and with a diffusion-weighted imaging (DWI) lesion no greater than 70 mL and FLAIR without a well defined hyperintense lesion that is more than 1/3 of the MCA territory.

• Pre-morbid modified Rankin score of 0 or 1.

Locations
United States
Maryland
Johns Hopkins Bayview Medical Center
Baltimore
The Johns Hopkins Hospital
Baltimore
Time Frame
Start Date: 2013-01
Completion Date: 2015-12
Participants
Target number of participants: 20
Treatments
Experimental: IV tPA
Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
Related Therapeutic Areas
Sponsors
Collaborators: Genentech, Inc.
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov